Werewolf Therapeutics Inc. has received a deficiency letter from the Nasdaq Stock Market, notifying the company that its common stock has closed below the $1.00 minimum bid price required for continued listing on the Nasdaq Global Select Market for 30 consecutive business days. The company now has 180 calendar days, expiring August 3, 2026, to regain compliance by achieving a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. If compliance is not regained within this period, Werewolf Therapeutics may be eligible for an additional 180-day compliance period by transferring to the Nasdaq Capital Market, provided it meets certain requirements. Failure to comply could result in delisting, though the company has the right to appeal any delisting determination.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-041305), on February 06, 2026, and is solely responsible for the information contained therein.